wdnering,

Thanks for sharing your thoughts so candidly. One cannot help but be negative after a series of disappointing developmentes confirmed by precipitous decline in the company's market cap. My feelings are not much different.

Here is the real problem. In my gut I also have another feeling. A feeling that tells me that those who are buying or holding on now would very happy two years from now. And I want to be a part of that.

For me it boils down to one thing. Do I think that Afrezza is approvable? Will it be approved eventually?

Pfizer developed a dud, but it was approved by the FDA. Mannkind has a superior product that has also positively addressed all problems associated with Exubra. That and all the available information about Afrezza leads me to think that indeed Afrezza is approvable and will eventaully be approved.

So my answer is yes, Afrezza is approvable, and will eventually be approved.

Two things separates us from that moment when Afrezza will be approved. Two years of time, and approximately $500M of funds.

I recall that Pfizer spent $3B to develop Exubra. With the additional funding, Mannkind will still have spent less to bring Afrezza to market. With all its failures, that is an accomplishment deserving of credit.

I think due to the recent problems and the cost to remedy these, investors will make less than what was originally anticipated. But the eventuall rewards will still be very satisfying.

With these thoughts I am trying to hang in there and somehow maintain an approroprite perspective.